Q2 FY27 revenue up 39.5%; EBITDA margin target of 19% plus by Q4

Management guided margin improvementOrder pipeline disclosedInvestor Communications View source PDF Explain this filing

INDGN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹612.50

prior close

₹617.05

announcement price

After-mkt

timing

Nifty Microcap 250market+2.2%-1.8% vs market

Healthcare Research Analytics & Technology peers, median of 5sector+2.8%-2.4% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 2.4 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.3

15m

-0.2

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+2.2-1.8+2.8-2.4

Next day

+0.3+3.3-3.0+4.4-4.1

-0.4pendingpending+2.0-2.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 39.5% year on year to INR11,223 million and 5.6% quarter on quarter. EBITDA was INR1,873 million, with a 16.7% margin, and profit after tax was INR1,123 million. Management expects efficiency gains to lift quarterly EBITDA margin to 19% or more by Q4. Nine deal wins and a healthy pipeline support the outlook; BioPharm delivered about $1.5 million in annual savings.

Likely market impact

Successful margin recovery and new deals could support earnings and sentiment, though Q4 execution and slower client ramps remain key risks.